摘要
| 原文 | 英語 |
|---|---|
| 頁（從 - 到） | 147-159 |
| 頁數 | 13 |
| 期刊 | 放射治療與腫瘤學 |
| 卷 | 7 |
| 發行號 | 3 |
| DOIs | |
| 出版狀態 | 已發佈 - 2000 |
指紋
Keywords
- 立體定位放射治療
- 惡性膠狀瘤
- 存活率
引用此文
Fractiona Stereotactic Radiotherapy for Malignant Glioma. / 鍾道生; 邱仲峯(Jeng-Fong Chiou); 高仲瑜; 蔡若婷(Jo-Ting Tsai); 葉啟源; 羅濟慶; 陳品玲(Ping-Ling Chen); 邱文達(Wen-Ta Chiou).
於: 放射治療與腫瘤學, 卷 7, 編號 3, 2000, p. 147-159.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Fractiona Stereotactic Radiotherapy for Malignant Glioma
AU - 鍾, 道生
AU - 邱, 仲峯(Jeng-Fong Chiou)
AU - 高, 仲瑜
AU - 蔡, 若婷(Jo-Ting Tsai)
AU - 葉, 啟源
AU - 羅, 濟慶
AU - 陳, 品玲(Ping-Ling Chen)
AU - 邱, 文達(Wen-Ta Chiou)
PY - 2000
Y1 - 2000
N2 - Purpose: This study is a retrospective analysis to evaluate the impact of fractionated stereotactic radiotherapy (FSRT) on malignant glioma. Material and Methods: Between June 1996 and May 1998, 37 patients with histology-cally proven WHO grade III or IV glioma (17 Anaplastic astrocytoma, 20 Glioblastoma multiforme) were treated at Taipei Medical University hospital with FSRT. External beam radiotherapy (EBRT) delivered a median dose of 46 Gy which is followed by stereotactic radiotherapy. A frameless fractionated stereotactic radiotherapy was used to boost the tumor bed, using daily fraction of 2.0 -3.0 Gy for 5 to 12 fractions. Non-coplanar arcs (4-8 arcs, median 4 arcs) with 1 to 2 isocenters were mostly used. Survival curves were calculated using the Kaplan-Meier method. Prognostic factors and different treatment variables were tested by univariate and multivariate analysis. Results: Overall median survival was 22 months. One year and 2-year survival rate were 60% and 30% respectively. Follow up imaging study showed tumor reduction greater than 50% in 6 patients (16%), reduction less than 50% or unchanged in 14 patients (38%) and progression in 17 of the 37 patients (46%). On analysis of different prognostic factors, patient's age (＜50 years and≧50 years), extent of surgical resection, and tumor volume (＜20 ml) were correlated with survival in univariate analysis (p＜0.05). Tumor volume and extent of surgical resection remained significant in multivariate analysis. The performance status remained stable for all patients during FSRT and only 5 patients (13%) suffered from treatment related acute toxicity with good medication control. Conclusion: Fractionated stereotactic radiotherapy provides a safe and feasible technique in the primary treatment of malignant gliomas. Although the overall survival and 1 year survival is encouraging, we did not observe a significant dose-effect relationship on overall and progression-free survival. Large series study with long term fallow-up is indicated.
AB - Purpose: This study is a retrospective analysis to evaluate the impact of fractionated stereotactic radiotherapy (FSRT) on malignant glioma. Material and Methods: Between June 1996 and May 1998, 37 patients with histology-cally proven WHO grade III or IV glioma (17 Anaplastic astrocytoma, 20 Glioblastoma multiforme) were treated at Taipei Medical University hospital with FSRT. External beam radiotherapy (EBRT) delivered a median dose of 46 Gy which is followed by stereotactic radiotherapy. A frameless fractionated stereotactic radiotherapy was used to boost the tumor bed, using daily fraction of 2.0 -3.0 Gy for 5 to 12 fractions. Non-coplanar arcs (4-8 arcs, median 4 arcs) with 1 to 2 isocenters were mostly used. Survival curves were calculated using the Kaplan-Meier method. Prognostic factors and different treatment variables were tested by univariate and multivariate analysis. Results: Overall median survival was 22 months. One year and 2-year survival rate were 60% and 30% respectively. Follow up imaging study showed tumor reduction greater than 50% in 6 patients (16%), reduction less than 50% or unchanged in 14 patients (38%) and progression in 17 of the 37 patients (46%). On analysis of different prognostic factors, patient's age (＜50 years and≧50 years), extent of surgical resection, and tumor volume (＜20 ml) were correlated with survival in univariate analysis (p＜0.05). Tumor volume and extent of surgical resection remained significant in multivariate analysis. The performance status remained stable for all patients during FSRT and only 5 patients (13%) suffered from treatment related acute toxicity with good medication control. Conclusion: Fractionated stereotactic radiotherapy provides a safe and feasible technique in the primary treatment of malignant gliomas. Although the overall survival and 1 year survival is encouraging, we did not observe a significant dose-effect relationship on overall and progression-free survival. Large series study with long term fallow-up is indicated.
KW - Stereotactic radiotherapy
KW - Glioma
KW - survival
KW - 立體定位放射治療
KW - 惡性膠狀瘤
KW - 存活率
U2 - 10.6316/TRO/200007(3)147
DO - 10.6316/TRO/200007(3)147
M3 - Article
VL - 7
SP - 147
EP - 159
JO - 放射治療與腫瘤學
JF - 放射治療與腫瘤學
SN - 1023-988x
IS - 3
ER -